ライフサイエンスコーパス: Thymoglobulin

1 after polyclonal antibody therapy (ATGAM or thymoglobulin).

2 1.01-1.40, relative to patients treated with thymoglobulin).

3 T-cell line (ATG-Fresenius) or thymus cells (Thymoglobulin).

4 performed in EBV-naive recipients receiving Thymoglobulin.

5 ute to the long-term results associated with Thymoglobulin.

6 ximab or high immune responders treated with thymoglobulin.

7 rder (PTLD) with the Atgam arm and none with Thymoglobulin.

8 d in the biopsies from patients treated with Thymoglobulin.

9 provide insight into mechanisms of action of Thymoglobulin.

10 The use of thymoglobulin (0.72, P=0.02) and IL-2RA (0.67, P=0.004)

11 at 6 months but was not different at 1 year (thymoglobulin: 0.77, P=0.05; IL-2RA:0.81, P=0.11) in HLA

12 eatment with i.v.IG 100 mg/kg for 3 days and Thymoglobulin 1.5 mg/kg for 5 days after transplantation

13 Three to six doses of Thymoglobulin (1 mg/kg/dose) were administered during th

14 A 7-day course of thymoglobulin (1.5 mg/kg per day) was begun on postopera

15 Subjects received 7-14 days of Thymoglobulin (1.5 mg/kg/ day) or Atgam (15 mg/kg/day).

16 on day 0, 7, 14), OKT 3 (5 mg/day x0-7), or thymoglobulin (1.5 mg/kg/day x0-10).

17 uzumab (22 patients) or cyclophosphamide and thymoglobulin (129 patients) followed by infusion of unm

18 after therapy, occurred less frequently with Thymoglobulin (17%) versus Atgam (36%) (P=0.011).

19 y recipients were given basiliximab (232) or thymoglobulin (28) induction, and sirolimus/steroids.

20 A regimen of Thymoglobulin, 30 days of SRL, and DBM infusion induced

21 ion were highest among patients treated with thymoglobulin (42% at 1 year).

22 improvement in posttreatment biopsy results (Thymoglobulin 65% and Atgam 50%; P=0.15) were not statis

23 eatinine levels as a percentage of baseline (Thymoglobulin 72% and Atgam 80%; P=0.43), and improvemen

24 Day 30 graft survival rates (Thymoglobulin 94% and Atgam 90%, P=0.17), day 30 serum c

25 the "event-free survival," was superior with Thymoglobulin (94%) compared with Atgam (63%; P=0.0005).

26 dy was to compare the efficacy and safety of Thymoglobulin (a rabbit-derived polyclonal antibody) to

27 Thymoglobulin, a rabbit anti-human thymocyte globulin, w

28 Thymoglobulin, a rabbit polyclonal antithymocyte globuli

29 d ischemia time, or total number of doses of Thymoglobulin administered.

30 Intraoperative Thymoglobulin administration was associated with signifi

31 s of this study indicate that intraoperative Thymoglobulin administration, in adult cadaveric renal t

32 pression therapy consisted of induction with thymoglobulin and a combination of tacrolimus, mycopheno

33 ed to compare the outcomes of induction with Thymoglobulin and alemtuzumab in KTRs through paired-kid

34 harge was lowest among patients treated with thymoglobulin and alemtuzumab.

35 Thymoglobulin and basiliximab induction and tacrolimus-b

36 Treatment with T-cell-directed therapies (thymoglobulin and daclizumab, all patients), alone or wi

37 atients received dual induction therapy with thymoglobulin and daclizumab, and low-dose maintenance t

38 erated analogously to the commercial product Thymoglobulin and in vivo activities were evaluated, inc

39 this study was to investigate the effect of Thymoglobulin and intravenous immunoglobulin (i.v.IG) th

40 All patients received induction therapy with thymoglobulin and maintenance immunosuppression with Tac

41 ressive protocol consisted of induction with thymoglobulin and maintenance with tacrolimus with or wi

42 unosuppression, consisting of induction with thymoglobulin and prednisone for the first 5 days.

43 ge charges per patient for the total dose of thymoglobulin and six CD3 determinations were $7305.

44 onsisting of rabbit anti-thymocyte globulin (Thymoglobulin) and the monoclonal antibody to CD20 ritux

45 e of therapy with corticosteroids, PL, IVIG, Thymoglobulin, and Rituximab (three patients) or Campath

46 The Thymoglobulin Antibody Immunosuppression in Living Donor

47 98.4% and 98.2% at 12 months as recorded in Thymoglobulin Antibody Immunosuppression in Living Donor

48 Immunosuppression consisted of Thymoglobulin antibody induction, tacrolimus, mycophenol

49 ibody induction therapy with alemtuzumab and Thymoglobulin appear equally effective in deceased donor

50 nic steroids (n=16), all in combination with thymoglobulin as induction agent, tacrolimus and mycophe

51 ts received antithymocyte globulin (ATGAM or thymoglobulin) as induction therapy or to treat steroid-

52 ospital pharmacy charge for a 100-mg dose of thymoglobulin at this center was $2,165, and the laborat

53 basiliximab (BSX) is different from that of Thymoglobulin (ATG) in this regard.

54 transplantation after induction therapy with Thymoglobulin, ATG-Fresenius S (ATG-F), and a control gr

55 ney transplants in 2001 to 2005 managed with thymoglobulin, basiliximab, or no antibody induction and

56 No recurrent rejection occurred with Thymoglobulin compared with 33% with Atgam (P=NS).

57 tion, "event-free survival," was higher with thymoglobulin compared with Atgam (48% vs. 29%; P=0.011)

58 l types of cancer was numerically lower with thymoglobulin compared with Atgam (8% vs. 21%, P=NS).

59 ulin vs. 3.15 Atgam; 16.7% improvement) from thymoglobulin compared with Atgam.

60 atistical approaches suggests superiority of thymoglobulin compared with basiliximab or no antibody i

61 er rates of the 6-month triple endpoint with thymoglobulin compared with basiliximab when steroids we

62 A combination of Thymoglobulin, continuous SRL, and rituximab caused graf

63 esigned trial included patients who received Thymoglobulin, corticosteroids, an antimetabolite, and c

64 nal transplant recipients receiving combined thymoglobulin/daclizumab induction along with reduced ta

65 g either MMF or EC-MPS along with a combined thymoglobulin/daclizumab induction, low tacrolimus dosin

66 ated with 7 doses of antithymocyte globulin (Thymoglobulin, day 1 to 9), sirolimus, and DBM infusion

67 essive therapy with the anti-T-cell antibody Thymoglobulin decreases the incidence of acute rejection

68 nalysis of 14 different manufactured lots of thymoglobulin demonstrates the overall consistency of th

69 The transcriptional pattern induced by Thymoglobulin differed from ATG-F in 18 differentially e

70 The mean individual thymoglobulin dose was 104 mg (1.4 mg/kg), and the total

71 studies provide the first demonstration that thymoglobulin effectively inhibits CXCR4/SDF-1alpha-driv

72 Rabbit anti-thymocyte globulin (Thymoglobulin) effectively treats transplant rejection b

73 (minimization) group of 22 patients received thymoglobulin followed by sirolimus and reduced-dose CsA

74 nted immediately before this series received thymoglobulin followed by sirolimus, reduced-dose CsA, a

75 iews our experience with the substitution of thymoglobulin for basiliximab as induction therapy for r

76 imab for low-immunologic risk recipients and thymoglobulin for high-risk recipients leads to prompt r

77 25 mg/m(2)) and melphalan (140 mg/m(2)) plus thymoglobulin (for mismatched donors).

78 uppression consisted of polyclonal antibody (Thymoglobulin) for 5 days, prednisone intraoperatively a

79 d with rabbit antithymocyte globulin (rATG) (Thymoglobulin [Genzyme] or ATG-Fresenius S [Fresenius, M

80 Rabbit antithymocyte globulin (rATG; thymoglobulin, Genzyme) in combination with cyclosporine

81 n was seen in 15 (68%) of 22 patients in the Thymoglobulin group and 28 (73%) of 38 in the basilixima

82 ansplant lymphoproliferative disorder in the thymoglobulin group and there were two cases in the Atga

83 al clustering analysis clearly separated the Thymoglobulin group from the ATG-F group, while the cont

84 Patients in the Thymoglobulin group were older (P=0.16), showed higher c

85 One patient in the Thymoglobulin group who suffered primary graft nonfuncti

86 2 mL/min vs. 65+/-19 mL/min; P=0.065) in the thymoglobulin group.

87 for the alemtuzumab group and 87.5% for the Thymoglobulin group.

88 survival was 89.3% overall and 91.7% in the thymoglobulin group.

89 e control group had a similar profile as the Thymoglobulin group.

90 trend toward lower vaccine responses in the Thymoglobulin group.

91 remained lower (11% vs. 42%, P=0.004) in the thymoglobulin group.

92 recipients comparing antithymocyte globulin (Thymoglobulin) (group A, N=43) versus alemtuzumab (group

93 pients from cadaver donors, group A received Thymoglobulin, group B received Alemtuzumab, and group C

94 = 0.97) were similar for alemtuzumab versus Thymoglobulin groups.

95 als were also similar for alemtuzumab versus Thymoglobulin groups.

96 cluded 1149 patients each in alemtuzumab and Thymoglobulin groups.

97 Intent-to-treat analysis demonstrated that Thymoglobulin had a higher rejection reversal rate than

98 In the Thymoglobulin high-risk group, the transcriptome profile

99 In this analysis, the use of Thymoglobulin in live-donor renal transplantation was as

100 ce with rabbit antithymocyte globulin (rATG; Thymoglobulin) in living donor renal transplant recipien

101 ly 5 mg/kg of rabbit antithymocyte globulin (Thymoglobulin) in the hours before transplantation, unde

102 All lots of thymoglobulin induced functionally immunosuppressive reg

103 uman peripheral blood mononuclear cells with thymoglobulin induces CD4+CD25(high)Foxp3+ regulatory T

104 an (HR, 2.64; 95% CI, 1.37-5.07; P = 0.003), thymoglobulin induction (HR, 2.18; 95% CI, 1.38-3.43; P

105 Thymoglobulin induction (HR, 2.50; 95% CI, 1.02-6.13; P

106 donor in such a way that 1 patient received Thymoglobulin induction and recipient of the mate kidney

107 unoglobulin infusion before LDLT followed by thymoglobulin induction and splenectomy, maintenance wit

108 l data of live-donor recipients who received Thymoglobulin induction and standard maintenance immunos

109 Most patients received thymoglobulin induction and were maintained on tacrolimu

110 By including recipient age and thymoglobulin induction as variables in a multivariate l

111 ransplantation to SPK transplantation in the Thymoglobulin induction era.

112 d trial of 40 consecutive patients receiving thymoglobulin induction for 3 days and followed for 1 ye

113 f live-donor renal transplants that received Thymoglobulin induction from May 1996 through 2003.

114 a novel immunosuppressive protocol including thymoglobulin induction in combination with sirolimus an

115 n of the nuclear factor-kappaB pathway after Thymoglobulin induction in vivo is likely to explain the

116 Thymoglobulin induction regimen led to a low incidence o

117 performed a prospective randomized study of Thymoglobulin induction therapy in adult cadaveric renal

118 sion, non-heart-beating donors) who received thymoglobulin induction therapy were included.

119 d to receive intraoperative or postoperative Thymoglobulin induction therapy.

120 spectively studied the effects of i.v.IG and Thymoglobulin induction treatment in B-cell CDC, and T-

121 Our results indicate that i.v.IG and Thymoglobulin induction treatment may facilitate kidney

122 Thus, Thymoglobulin induction was associated with a decreased

123 When combined with Thymoglobulin induction, an antimetabolite, and corticos

124 C versus CsA, in a regimen that consisted of Thymoglobulin induction, an antimetabolite, and predniso

125 tment increased with DSA levels and included thymoglobulin induction, plasmapheresis, and intravenous

126 Thymoglobulin induction, tacrolimus, and mycophenolate m

127 g an immunosuppressive regimen consisting of Thymoglobulin induction, tacrolimus, mycophenolate mofet

128 ontinuation of prednisone (RDP, <1 week) and thymoglobulin induction.

129 tis C virus in liver recipients who received thymoglobulin induction.

130 up of 266 consecutive pancreas recipients on Thymoglobulin (induction) and tacrolimus (maintenance).

131 The impact of induction (thymoglobulin, interleukin-2 receptor antagonists [IL-2R

132 of common induction treatments (alemtuzumab, thymoglobulin, interleukin-2 receptor blockers, and no i

133 Standard immunosuppression with Thymoglobulin/interleukin 2 receptor blocker and mycophe

134 bulin, we initiated a protocol to administer thymoglobulin intermittently based on peripheral blood C

135 Thymoglobulin is a T-cell-depleting polyclonal rabbit an

136 Three-day induction with thymoglobulin is as effective and safe as seven days, de

137 clonal rabbit anti-human thymocyte globulin (Thymoglobulin) is used clinically for immunosuppression

138 lus and taper, with specific cases requiring thymoglobulin, IVIg, rituximab, or plasmapheresis.

139 In controls, IS consisted of thymoglobulin, maintenance prednisone, azathioprine, and

140 ethotrexate regimen with a murine version of Thymoglobulin (mATG) for effects on anti-mATG Abs and ca

141 sights into nondepletive mechanisms by which thymoglobulin may generate durable immunoregulation and

142 RDP using thymoglobulin, mycophenolate mofetil, and CsA in selecte

143 isted of prednisone tapered off over 6 days, thymoglobulin, mycophenolate mofetil, and cyclosporine A

144 Sixty patients (Thymoglobulin n=22 and basiliximab n=38) were included.

145 s who received either basiliximab (n=115) or thymoglobulin (n=30) in combination with sirolimus and p

146 d 2:1 in a double-blinded fashion to receive Thymoglobulin (n=48) at 1.5 mg/kg intravenously or Atgam

147 y with polyclonal antibody, ATGAM (n=127) or Thymoglobulin (n=71), from December 1, 1992, to January

148 Patients were treated with plasmapheresis, thymoglobulin/OKT3, and corticosteroids.

149 Whether alemtuzumab is more effective than Thymoglobulin or anti-interleukin 2 receptor antibodies

150 ) disease occurred after the first year with Thymoglobulin or Atgam (13% vs. 33%, P=0.056).

151 acy at 10 years among patients randomized to thymoglobulin or Atgam induction in a single center, ran

152 kidney transplant recipients having received Thymoglobulin or basiliximab as induction therapy.

153 transplant recipients having received either Thymoglobulin or basiliximab.

154 Fewer adverse events occurred with Thymoglobulin (P=0.013).

155 significantly shorter for the intraoperative Thymoglobulin patient group.

156 Two alemtuzumab and three Thymoglobulin patients suffered rejection episodes.

157 Physiologic levels of thymoglobulin produced nondepletive immunomodulatory act

158 Thymoglobulin (Rabbit Anti-Thymocyte Globulin) was used

159 In the present study, 14 lots of thymoglobulin (rabbit ATG) were analyzed and compared fo

160 Thymoglobulin, rabbit antithymocyte globulin (RATG), has

161 Thymoglobulin (rATG) has become the agent of choice for

162 d the rabbit antihuman thymocyte preparation Thymoglobulin (rATG) on phytohemagglutinin-activated hum

163 he incidence of acute rejection was lower in Thymoglobulin recipients versus ATGAM recipients (33% vs

164 ein-Barr virus (EBV) infection was higher in Thymoglobulin recipients versus ATGAM recipients (8% vs.

165 for ATGAM recipients and 32+/-15 months for Thymoglobulin recipients.

166 Brief (7-day) induction with Thymoglobulin resulted in less frequent and less severe

167 Treatment with Thymoglobulin resulted in profound depletion of CD4+ and

168 Standard immunosuppression included thymoglobulin-rituximab induction and tacrolimus-prednis

169 group of 48 patients that received 7 days of thymoglobulin served as controls.

170 Patients who received Thymoglobulin showed lower CD4(+) cell counts and lower

171 thymus transplantation after treatment with Thymoglobulin shows promise as therapy for infants with

172 Thymoglobulin significantly decreased rejection in the f

173 recipients received an induction protocol of thymoglobulin, sirolimus, reduced-dose cyclosporine, and

174 This study aims to determine the impact of thymoglobulin-sirolimus-cyclosporine immunosuppression o

175 The Thymoglobulin, SRL, and DBM protocol is simple and produ

176 initial immunosuppressive protocol included thymoglobulin, tacrolimus, prednisone, and mycophenolate

177 OKT3 was recently withdrawn from the market, thymoglobulin (TG) became the principal treatment for SR

178 Leukopenia was more common with Thymoglobulin than Atgam (56% vs. 4%; P<0.0001) during i

179 Rejection was less severe with Thymoglobulin than Atgam (P=0.02).

180 The rate of acute rejection was lower with Thymoglobulin than Atgam (relative risk=0.09; P=0.009).

181 nce of cytomegalovirus disease was less with Thymoglobulin than Atgam at 6 months (10% vs. 33%; P=0.0

182 pletion was maintained more effectively with Thymoglobulin than Atgam both at the end of therapy (P=0

183 Intermittent thymoglobulin therapy, based on peripheral blood CD3+ ly

184 ymphocyte count remained below baseline with Thymoglobulin throughout the study (P<0.007), but with A

185 daclizumab (DAC), the safety and efficacy of thymoglobulin (TMG) was tested as an alternative inducti

186 nosuppressive drugs, as seen in the Study of Thymoglobulin to arrest Type 1 Diabetes (START) trial of

187 eated low immune responders (10%, P=0.04) or thymoglobulin-treated high immune responders (3%, P=0.01

188 By 1 year after transplantation, 4% of Thymoglobulin-treated patients experienced acute rejecti

189 Thymoglobulin treatment was discontinued once therapeuti

190 Thymoglobulin use (P = 0.04) and positive donor CMV stat

191 lts of a randomized, double-blinded trial of Thymoglobulin versus Atgam for induction therapy in rena

192 article compares the safety and efficacy of Thymoglobulin versus Atgam induction through 5 years.

193 tion (92% vs. 66%, P=0.007) were higher with Thymoglobulin versus Atgam.

194 n steroids were absent, risk reduction among thymoglobulin versus basiliximab-treated patients was of

195 There were 0.53 QALYs gained (3.68 thymoglobulin vs. 3.15 Atgam; 16.7% improvement) from th

196 The first dose (1.5 mg/kg) of thymoglobulin was administered intraoperatively.

197 t 3-days of induction immunosuppression with thymoglobulin was as effective and safe as a 7-day cours

198 Thymoglobulin was associated with higher event-free surv

199 erapy in renal transplantation revealed that Thymoglobulin was associated with higher event-free surv

200 This long-term follow-up showed that thymoglobulin was associated with higher event-free surv

201 Thymoglobulin was associated with profound lymphopenia a

202 D3, CD11a, and CD45 antigen specificities in thymoglobulin was determined using flow cytometry to mea

203 Thymoglobulin was found to be superior to Atgam in rever

204 Thymoglobulin was given at a cumulative dose of 8 mg/kg,

205 ated by the same process used to manufacture thymoglobulin, was used alone or in combination with CTL

206 T-cell depletion and prolonged half-life of thymoglobulin, we initiated a protocol to administer thy

207 Four batches of ATG-Fresenius and Thymoglobulin were compared regarding their capacity to

208 charge for daily administration of 104 mg of thymoglobulin (which was the mean dose) for 6 days (mean

209 ith tacrolimus monotherapy, or four doses of Thymoglobulin with tacrolimus, mycophenolate, and steroi

210 rrence was observed in patients treated with thymoglobulin, yet this observation can only be validate